<p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT - 获取免费报告）在 TD Cowen 发布给投资者的研究报告中被股票研究分析师升级为 “强力买入” 评级，Zacks.com 报道。</p>
<ul>
<li>你可能不知道的突破性动量股票</li>
</ul>
<p>其他几家研究公司也最近对 EYPT 发表了看法。瑞穗证券在 10 月 20 日的报告中将 Eyepoint Pharmaceuticals 的目标价格设定为 28.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对 Eyepoint Pharmaceuticals 股票的 “卖出（d-）” 评级。加拿大皇家银行在 11 月 6 日的研究报告中将 Eyepoint Pharmaceuticals 的目标价格从 28.00 美元上调至 39.00 美元，并给予该公司 “跑赢大盘” 的评级。最后，Cantor Fitzgerald 在 11 月 25 日的研究报告中将 Eyepoint Pharmaceuticals 的股票评级提升至 “强力买入”。两位投资分析师对该股票给予了强力买入评级，五位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，Eyepoint Pharmaceuticals 目前的平均评级为 “买入”，平均目标价格为 30.00 美元。</p>
<p><strong>查看我们关于 EYPT 的最新报告</strong></p>
<h2>Eyepoint Pharmaceuticals 股价上涨 2.2%</h2>
<p>纳斯达克代码：EYPT 的股票在周五以 17.43 美元开盘。该公司的市值为 14.4 亿美元，市盈率为-5.83，贝塔值为 1.67。Eyepoint Pharmaceuticals 的 1 年最低价为 3.91 美元，1 年最高价为 19.11 美元。该公司的 50 日移动平均价格为 13.70 美元，200 日移动平均价格为 12.03 美元。</p>
<p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT - 获取免费报告）在 11 月 5 日星期三发布了季度财报。该公司报告每股收益为（0.85 美元），低于分析师一致预期的（0.77 美元）8 美分。Eyepoint Pharmaceuticals 的净利润率为-485.95%，股本回报率为-76.13%。该公司在本季度的收入为 97 万美元，而分析师预期为 333 万美元。作为一个整体，股票分析师预测 Eyepoint Pharmaceuticals 在本年度将发布-2.13 的每股收益。</p>
<h2>对 Eyepoint Pharmaceuticals 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Nisa Investment Advisors LLC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股比例提高了 1636.5%。Nisa Investment Advisors LLC 现在拥有 2900 股该公司的股票，价值 27000 美元，此前在此期间又购买了 2733 股。阿拉斯加州财政部在第三季度购买了 Eyepoint Pharmaceuticals 的新头寸，价值约 50000 美元。拉塞尔投资集团有限公司在第三季度购买了 Eyepoint Pharmaceuticals 的新头寸，价值约 76000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股比例提高了 218.3%。Tower Research Capital LLC TRC 现在拥有 8700 股该公司的股票，价值 82000 美元，此前在上个季度又收购了 5967 股。最后，R Squared Ltd 在第二季度购买了 Eyepoint Pharmaceuticals 的新股份，价值约 100000 美元。99.41% 的股票由机构投资者持有。</p>
<h2>关于 Eyepoint Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Eyepoint Pharmaceuticals, Inc 是一家生物制药公司，专注于开发和商业化治疗眼部疾病的疗法。该公司的专有平台集中于持续释放的制剂，旨在改善药物向眼后段的输送，解决通常需要重复玻璃体内注射或密集局部治疗的情况。Eyepoint 的商业策略结合了内部销售和市场能力与有针对性的合作伙伴关系，将其疗法带给美国的眼科医生和视网膜专家。</p>
<p>Eyepoint 的主要产品包括 YUTIQ，一种氟氯噻吨醇玻璃体内植入物，旨在预防影响眼后段的非感染性葡萄膜炎的复发，以及 DEXYCU，一种用于眼科手术后炎症的地塞米松眼内悬浮液。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Eyepoint Pharmaceuticals 更好</li>
<li>如何投资蓝筹股</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>股票平均计算器</li>
<li>耐克在收益上超出预期，但在中国面临困难并遭遇关税</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVlQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVlQVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Eyepoint Pharmaceuticals 吗？</h2>
<p>在你考虑 Eyepoint Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场意识到之前...而 Eyepoint Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eyepoint Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

EYPT

<p>TD Cowen 将 EyePoint Pharmaceuticals 的评级上调至 “强力买入”。其他公司如瑞穗证券和加拿大皇家银行分别设定了 28 美元和 39 美元的目标价。Cantor Fitzgerald 也给予了 “强力买入” 的评级。该股票开盘价为 17.43 美元，市值为 14.4 亿美元。分析师预测该年度每股收益为 -2.13。机构投资者持有该股票的 99.41%。EyePoint 专注于眼科疾病治疗，产品包括 YUTIQ 和 DEXYCU</p>

<p>Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) was upgraded by equities research analysts at TD Cowen to a &#34;strong-buy&#34; rating in a research note issued to investors on Friday,Zacks.com reports.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT - 获取免费报告）在 TD Cowen 发布给投资者的研究报告中被股票研究分析师升级为 “强力买入” 评级，Zacks.com 报道。</p>
</div><ul>
<li>Breakout Momentum Plays You May Not Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能不知道的突破性动量股票</li>
</ul>
</div><p>Several other research firms have also recently weighed in on EYPT. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a report on Monday, October 20th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Eyepoint Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of &#34;Buy&#34; and an average target price of $30.00.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 EYPT 发表了看法。瑞穗证券在 10 月 20 日的报告中将 Eyepoint Pharmaceuticals 的目标价格设定为 28.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对 Eyepoint Pharmaceuticals 股票的 “卖出（d-）” 评级。加拿大皇家银行在 11 月 6 日的研究报告中将 Eyepoint Pharmaceuticals 的目标价格从 28.00 美元上调至 39.00 美元，并给予该公司 “跑赢大盘” 的评级。最后，Cantor Fitzgerald 在 11 月 25 日的研究报告中将 Eyepoint Pharmaceuticals 的股票评级提升至 “强力买入”。两位投资分析师对该股票给予了强力买入评级，五位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，Eyepoint Pharmaceuticals 目前的平均评级为 “买入”，平均目标价格为 30.00 美元。</p>
</div><p><strong>View Our Latest Report on EYPT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 EYPT 的最新报告</strong></p>
</div><h2>Eyepoint Pharmaceuticals Trading Up 2.2%</h2>
<div class="lb-trans"><h2>Eyepoint Pharmaceuticals 股价上涨 2.2%</h2>
</div><p>Shares of NASDAQ:EYPT opened at $17.43 on Friday. The stock has a market capitalization of $1.44 billion, a P/E ratio of -5.83 and a beta of 1.67. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $19.11. The business has a 50-day moving average price of $13.70 and a two-hundred day moving average price of $12.03.</p>
<div class="lb-trans"><p>纳斯达克代码：EYPT 的股票在周五以 17.43 美元开盘。该公司的市值为 14.4 亿美元，市盈率为-5.83，贝塔值为 1.67。Eyepoint Pharmaceuticals 的 1 年最低价为 3.91 美元，1 年最高价为 19.11 美元。该公司的 50 日移动平均价格为 13.70 美元，200 日移动平均价格为 12.03 美元。</p>
</div><p>Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million. As a group, equities analysts predict that Eyepoint Pharmaceuticals will post -2.13 EPS for the current year.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals（纳斯达克代码：EYPT - 获取免费报告）在 11 月 5 日星期三发布了季度财报。该公司报告每股收益为（0.85 美元），低于分析师一致预期的（0.77 美元）8 美分。Eyepoint Pharmaceuticals 的净利润率为-485.95%，股本回报率为-76.13%。该公司在本季度的收入为 97 万美元，而分析师预期为 333 万美元。作为一个整体，股票分析师预测 Eyepoint Pharmaceuticals 在本年度将发布-2.13 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Eyepoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Eyepoint Pharmaceuticals 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company's stock valued at $27,000 after purchasing an additional 2,733 shares during the period. State of Alaska Department of Revenue bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $50,000. Russell Investments Group Ltd. bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $76,000. Tower Research Capital LLC TRC lifted its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after acquiring an additional 5,967 shares during the last quarter. Finally, R Squared Ltd bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth approximately $100,000. 99.41% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持股。Nisa Investment Advisors LLC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股比例提高了 1636.5%。Nisa Investment Advisors LLC 现在拥有 2900 股该公司的股票，价值 27000 美元，此前在此期间又购买了 2733 股。阿拉斯加州财政部在第三季度购买了 Eyepoint Pharmaceuticals 的新头寸，价值约 50000 美元。拉塞尔投资集团有限公司在第三季度购买了 Eyepoint Pharmaceuticals 的新头寸，价值约 76000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Eyepoint Pharmaceuticals 的持股比例提高了 218.3%。Tower Research Capital LLC TRC 现在拥有 8700 股该公司的股票，价值 82000 美元，此前在上个季度又收购了 5967 股。最后，R Squared Ltd 在第二季度购买了 Eyepoint Pharmaceuticals 的新股份，价值约 100000 美元。99.41% 的股票由机构投资者持有。</p>
</div><h2>About Eyepoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Eyepoint Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals, Inc 是一家生物制药公司，专注于开发和商业化治疗眼部疾病的疗法。该公司的专有平台集中于持续释放的制剂，旨在改善药物向眼后段的输送，解决通常需要重复玻璃体内注射或密集局部治疗的情况。Eyepoint 的商业策略结合了内部销售和市场能力与有针对性的合作伙伴关系，将其疗法带给美国的眼科医生和视网膜专家。</p>
</div><p>Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.</p>
<div class="lb-trans"><p>Eyepoint 的主要产品包括 YUTIQ，一种氟氯噻吨醇玻璃体内植入物，旨在预防影响眼后段的非感染性葡萄膜炎的复发，以及 DEXYCU，一种用于眼科手术后炎症的地塞米松眼内悬浮液。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eyepoint Pharmaceuticals</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>Stock Average Calculator</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Eyepoint Pharmaceuticals 更好</li>
<li>如何投资蓝筹股</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>股票平均计算器</li>
<li>耐克在收益上超出预期，但在中国面临困难并遭遇关税</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVlQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=EYPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eyepoint Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Eyepoint Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Eyepoint Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场意识到之前...而 Eyepoint Pharmaceuticals 并不在名单上。</p>
</div><p>While Eyepoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eyepoint Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

EyePoint Pharmaceuticals（纳斯达克代码：EYPT）在 TD Cowen 的评级被上调至强力买入